ImageneBio (NASDAQ: IMA) names Bob Lally Principal Accounting Officer as Erin Butler departs

Rhea-AI Filing Summary

ImageneBio, Inc. announced that it has agreed to a mutual separation with Erin Butler, its Senior Vice President, Finance & Administration and Principal Accounting Officer, effective March 20, 2026. After that date, she will no longer serve as the company’s Principal Accounting Officer and is expected to receive severance benefits under her existing Severance Rights Agreement.

The board of directors has appointed Bob Lally, age 63, currently Senior Vice President, Finance & Operations, to serve as Principal Accounting Officer effective as of the same date. The filing describes Mr. Lally’s prior senior finance and operations roles at Ikena Oncology, Prevail Therapeutics and Arsanis, and notes he did not enter into any new material agreement, has no family relationships with directors or officers, and is not involved in related-party transactions requiring disclosure.

NASDAQ false 0001835579 0001835579 2026-03-12 2026-03-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 12, 2026

IMAGENEBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40287		81-1697316
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

12526 High Bluff Drive, Suite 345
San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 345-6265

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		IMA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 12, 2026, ImageneBio, Inc. (the “Company”) and Erin Butler, the Company’s Senior Vice President, Finance & Administration and Principal Accounting Officer, agreed to a mutual separation effective March 20, 2026 (the “Butler Separation Date”). Effective as of the Butler Separation Date, Ms. Butler will no longer serve as the Company’s Principal Accounting Officer.

The Company expects to enter into a separation agreement (the “Separation Agreement”) with Ms. Butler, pursuant to which Ms. Butler will receive the severance benefits set forth in her Severance Rights Agreement, dated October 21, 2024 and filed as Exhibit 10.16 to the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on July 29, 2025.

The Company’s board of directors has, effective as of the Butler Separation Date, appointed Bob Lally, our Senior Vice President, Finance & Operations, as the Company’s Principal Accounting Officer.

Bob Lally, age 63, has served as our Senior Vice President, Finance & Operations since July 2025. Previously, Mr. Lally served as Senior Vice President, Finance & Operations at our predecessor, Ikena Oncology, Inc. from December 2022 to July 2025. Mr. Lally served in various roles of increasing responsibility at Prevail Therapeutics Inc. where he served as Vice President, Finance from February 2019 through March 2021 and as Chief Operating Officer from March 2021 through June 2022. Prior to that, Mr. Lally served as Executive Director, Finance and Controller at Arsanis, Inc. from May 2016 through March 2019. Mr. Lally holds a B.S. in finance from the University of Massachusetts, Lowell.

Mr. Lally did not enter into any material plan, contract or arrangement with the Company in connection with his appointment as the Company’s principal accounting officer.

There are no family relationships between Mr. Lally and any of the Company’s current or former directors or executive officers. Mr. Lally is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IMAGENEBIO, INC.
Date: March 17, 2026				By:		/s/ Kristin Yarema
						Kristin Yarema, Ph.D.
						Chief Executive Officer

FAQ

What executive change did ImageneBio (IMA) disclose on March 12, 2026?

ImageneBio disclosed a mutual separation with Erin Butler, its Senior Vice President, Finance & Administration and Principal Accounting Officer, effective March 20, 2026. She will step down from the Principal Accounting Officer role and is expected to receive severance benefits under her existing Severance Rights Agreement.

Who will be ImageneBio’s new Principal Accounting Officer and when is it effective?

Bob Lally will become ImageneBio’s Principal Accounting Officer effective March 20, 2026. He currently serves as Senior Vice President, Finance & Operations and brings prior senior finance and operations experience from Ikena Oncology, Prevail Therapeutics, and Arsanis.

Will Erin Butler receive severance from ImageneBio (IMA) after her separation?

Erin Butler is expected to receive severance benefits under her Severance Rights Agreement dated October 21, 2024. The filing states she will receive the severance benefits set forth in that agreement following her mutual separation from ImageneBio effective March 20, 2026.

Did Bob Lally sign any new material agreement with ImageneBio upon his appointment?

The filing states that Bob Lally did not enter into any material plan, contract, or arrangement with ImageneBio in connection with his appointment as Principal Accounting Officer. His role expands to include that responsibility alongside his existing Senior Vice President, Finance & Operations position.

Are there any family or related-party relationships involving Bob Lally at ImageneBio?

ImageneBio states there are no family relationships between Bob Lally and any of the company’s current or former directors or executive officers. It also notes he is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K.

What is Bob Lally’s professional background before joining ImageneBio (IMA)?

Before joining ImageneBio, Bob Lally was Senior Vice President, Finance & Operations at Ikena Oncology, Inc., held finance and Chief Operating Officer roles at Prevail Therapeutics Inc., and served as Executive Director, Finance and Controller at Arsanis, Inc. He holds a B.S. in finance from the University of Massachusetts, Lowell.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 18.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.4 KB